Abbott Laboratories (ABT) Accumulated Expenses (2009 - 2026)

Abbott Laboratories has disclosed Accumulated Expenses across 18 years of filings, most recently posting $1.2 billion for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $1.2 billion, up 3.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 3.86% YoY), and the FY2025 annual result was $1.7 billion, up 2.59% from the prior year.
• Accumulated Expenses came in at $1.2 billion for Q1 2026 at Abbott Laboratories, down from $1.7 billion in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $1.7 billion in Q4 2025 to a low of $1.1 billion in Q1 2024.
• The 5-year median for Accumulated Expenses is $1.4 billion (2022), against an average of $1.4 billion.
• Across the five-year window, Accumulated Expenses dropped 4.27% in 2023 and grew 11.59% in 2025, its largest moves.
• Abbott Laboratories' Accumulated Expenses stood at $1.6 billion in 2022, then advanced by 2.63% to $1.6 billion in 2023, then increased by 6.51% to $1.7 billion in 2024, then increased by 2.59% to $1.7 billion in 2025, then sank by 30.54% to $1.2 billion in 2026.
• The last three Accumulated Expenses figures came in at $1.2 billion (Q1 2026), $1.7 billion (Q4 2025), and $1.7 billion (Q3 2025), per Business Quant data.